Publications by authors named "Doug G Altman"

Claim this Profile
E
Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330].
David E Neal, Chris Metcalfe, Jenny L Donovan, J Athene Lane, Michael Davis, Doug G Altman

Eur Urol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
David E Neal, Chris Metcalfe, Jenny L Donovan, J Athene Lane, Michael Davis, Doug G Altman

Eur Urol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Methods for evaluating medical tests and biomarkers.
Gowri Gopalakrishna, Miranda Langendam, Rob Scholten, Patrick Bossuyt, Mariska Leeflang, Doug Altman, Doug Altman, Doug Altman, Doug G Altman, Douglas G Altman, Doug Altman, Douglas G Altman, Douglas Altman, Douglas G Altman

Diagn Progn Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Explicit inclusion of treatment in prognostic modeling was recommended in observational and randomized settings.
Rolf H H Groenwold, Karel G M Moons, Romin Pajouheshnia, Doug G Altman, Gary S Collins

J Clin Epidemiol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges.
Richard D Riley, Joie Ensor, Kym I E Snell, Thomas P A Debray, Doug G Altman

BMJ· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abstracts of the 4th Meeting of the Core Outcome Measures in Effectiveness Trials (COMET) Initiative.
Elizabeth Gargon, Doug G Altman, Jane M Blazeby, Mike Clarke, Paula R Williamson

Trials· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proceedings of the 5th Meeting of the Core Outcome Measures in Effectiveness Trials (COMET) Initiative.
Sarah L Gorst, Doug G Altman, Jane M Blazeby, Mike Clarke, Elizabeth Gargon

Trials· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COMET initiative database: progress and activities update (2014).
Elizabeth Gargon, Paula R Williamson, Doug G Altman, Jane M Blazeby, Mike Clarke

Trials· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choosing important health outcomes for comparative effectiveness research: a systematic review.
Elizabeth Gargon, Binu Gurung, Nancy Medley, Doug G Altman, Jane M Blazeby

PLoS One· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of analysis methods for diagnostic imaging tests: problems with ROC AUC and confidence scores in CT colonography.
Susan Mallett, Steve Halligan, Gary S Collins, Doug G Altman

PLoS One· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Making randomised trials more efficient: report of the first meeting to discuss the Trial Forge platform.
Shaun Treweek, Doug G Altman, Peter Bower, Marion Campbell, Iain Chalmers

Trials· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic review of the use of an expertise-based randomised controlled trial design.
Jonathan A Cook, Andrew Elders, Charles Boachie, Ted Bassinga, Cynthia Fraser, Doug G Altman

Trials· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The distribution of clinical phenotypes of preterm birth syndrome: implications for prevention.
Fernando C Barros, Aris T Papageorghiou, Cesar G Victora, Julia A Noble, Ruyan Pang, Doug G Altman

JAMA Pediatr· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The likeness of fetal growth and newborn size across non-isolated populations in the INTERGROWTH-21st Project: the Fetal Growth Longitudinal Study and Newborn Cross-Sectional Study.
José Villar, Aris T Papageorghiou, Ruyan Pang, Eric O Ohuma, Leila Cheikh Ismail, Doug G Altman

Lancet Diabetes Endocrinol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project.
José Villar, Leila Cheikh Ismail, Cesar G Victora, Eric O Ohuma, Enrico Bertino, Doug G Altman

Lancet· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coronary artery bypass grafting in high-RISk patients randomised to off- or on-Pump surgery: a randomised controlled trial (the CRISP trial).
Chris A Rogers, Katie Pike, Helen Campbell, Barnaby C Reeves, Gianni D Angelini, Doug G Altman

Health Technol Assess· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of methods for specifying the target difference in randomised controlled trial sample size calculations: Two surveys of trialists' practice.
Jonathan A Cook, Jennifer M Hislop, Doug G Altman, Andrew H Briggs, Peter M Fayers

Clin Trials· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Red blood cell transfusion and mortality in trauma patients: risk-stratified analysis of an observational study.
Pablo Perel, Tim Clayton, Doug G Altman, Peter Croft, Ian Douglas

PLoS Med· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews.
Joel J Gagnier, Hal Morgenstern, Doug G Altman, Jesse Berlin, Stephanie Chang

BMC Med Res Methodol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study.
Fujian Song, Tengbin Xiong, Sheetal Parekh-Bhurke, Yoon K Loke, Alex J Sutton, Doug G Altman

BMJ· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal.
David M Kent, Peter M Rothwell, John P A Ioannidis, Doug G Altman, Rodney A Hayward

Trials· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bias due to changes in specified outcomes during the systematic review process.
Jamie J Kirkham, Doug G Altman, Paula R Williamson

PLoS One· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Ages and Stages Questionnaires in identifying children with neurosensory disability in the Magpie Trial follow-up study.
Ly-Mee Yu, Edmund Hey, Lex W Doyle, Barbara Farrell, Patsy Spark, Doug G Altman

Acta Paediatr· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis